Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

CONCLUSIONS: In patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. (Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988.).PMID:36877098 | DOI:10.1056/NEJMoa2213558

Source: JOP - March 6, 2023 Category: Gastroenterology Authors: Marius M Hoeper David B Badesch H Ardeschir Ghofrani J Simon R Gibbs Mardi Gomberg-Maitland Vallerie V McLaughlin Ioana R Preston Rogerio Souza Aaron B Waxman Ekkehard Gr ünig Grzegorz Kope ć Gisela Meyer Karen M Olsson Stephan Rosenkranz Yayun Xu Barry Source Type: research